Arndt Vogel: TACE combined with lenvatinib and pembrolizumab vs placebo for intermediate HCC

Arndt Vogel, Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School, shared a recent paper by him and colleagues on X:

“Off the press: TACE combined with lenvatinib and pembrolizumab vs placebo for intermediate HCC.

LEAP-012 phase 3.

ORR: 47 vs 33%, PFS 14.6 vs 10 months.

Proof of concept: TACE plus ICI improves outcomes.”

“Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study”

Authors: Masatoshi Kudo, Zhenggang Ren, Yabing Guo, Arndt Vogel, et al.

Arndt Vogel, MD, is a Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School. Leading the GI-Cancer Center and the Center for Personalized Medicine, his research focuses on translational and clinical studies in gastrointestinal cancer.

He’s actively engaged in various societies including ESMO, ASCO, and EASL. Additionally, he chairs the Hepatobiliary Cancer Study Group of the AIO, contributing significantly to clinical oncology in Germany. Within ESMO, he serves on the Guidelines Steering Committee.

More posts featuring Arndt Vogel.